Zymeworks To Report Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on March 5, 2025

Core Viewpoint - Zymeworks Inc. is set to report its fourth quarter and full year 2024 financial results on March 5, 2025, followed by a conference call and webcast to discuss the results and provide a corporate update [1] Company Overview - Zymeworks Inc. is a clinical-stage biotechnology company focused on developing novel, multifunctional biotherapeutics aimed at improving treatment for difficult-to-treat diseases such as cancer, inflammation, and autoimmune diseases [2] - The company utilizes its proprietary Azymetric™ technology to engineer and develop zanidatamab, a HER2-targeted bispecific antibody [2] - Zymeworks has exclusive agreements with BeiGene and Jazz Pharmaceuticals for the development and commercialization of zanidatamab in different territories [2] Product Development and Regulatory Approvals - The U.S. FDA has granted accelerated approval for Ziihera (zanidatamab-hrii) for the treatment of adults with previously-treated, unresectable or metastatic HER2-positive second-line biliary tract cancer, making it the first dual HER2-targeted bispecific antibody approved for this indication in the U.S. [2] - Zanidatamab is currently under regulatory review in the EU and China for second-line biliary tract cancer and is being evaluated in multiple global clinical trials for various HER2-expressing cancers [2] - Zymeworks is advancing a robust pipeline of wholly-owned product candidates, with Phase 1 studies for ZW171 and ZW191 actively recruiting, and investigational new drug applications for ZW220 and ZW251 planned for 2025 [2] Strategic Partnerships - The company has leveraged its therapeutic platforms through strategic partnerships with global biopharmaceutical companies, enhancing its product development capabilities [2]